208 related articles for article (PubMed ID: 25481044)
1. Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.
Jaganathan S; Malek E; Vallabhapurapu S; Vallabhapurapu S; Driscoll JJ
Oncotarget; 2014 Dec; 5(23):12358-70. PubMed ID: 25481044
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
Min H; Xu M; Chen ZR; Zhou JD; Huang M; Zheng K; Zou XP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):167-76. PubMed ID: 24842158
[TBL] [Abstract][Full Text] [Related]
3. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
4. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis.
Yousefi S; Perozzo R; Schmid I; Ziemiecki A; Schaffner T; Scapozza L; Brunner T; Simon HU
Nat Cell Biol; 2006 Oct; 8(10):1124-32. PubMed ID: 16998475
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
[TBL] [Abstract][Full Text] [Related]
7. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
8. Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer.
Song X; Kim SY; Zhang L; Tang D; Bartlett DL; Kwon YT; Lee YJ
Cell Death Dis; 2014 Oct; 5(10):e1504. PubMed ID: 25356873
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells.
Song IS; Kim HK; Lee SR; Jeong SH; Kim N; Ko KS; Rhee BD; Han J
Int J Cancer; 2013 Sep; 133(6):1357-67. PubMed ID: 23463417
[TBL] [Abstract][Full Text] [Related]
10. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.
Lou Z; Ren T; Peng X; Sun Y; Jiao G; Lu Q; Zhang S; Lu X; Guo W
J Int Med Res; 2013 Oct; 41(5):1505-19. PubMed ID: 23975859
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
13. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
[TBL] [Abstract][Full Text] [Related]
14. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
Escalante AM; McGrath RT; Karolak MR; Dorr RT; Lynch RM; Landowski TH
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1567-76. PubMed ID: 23572175
[TBL] [Abstract][Full Text] [Related]
15. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
16. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
17. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
18. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
19. Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
Ju D; Xie Y
Mol Med Rep; 2014 Nov; 10(5):2609-12. PubMed ID: 25174315
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.
Jagannathan S; Abdel-Malek MA; Malek E; Vad N; Latif T; Anderson KC; Driscoll JJ
Leukemia; 2015 Nov; 29(11):2184-91. PubMed ID: 26108695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]